Vincent C. Marconi, Athimalaipet V. Ramanan, Stephanie de Bono, Cynthia E. Kartman,
Venkatesh Krishnan, Ran Liao, Maria Lucia B. Piruzeli, Jason D. Goldman, Jorge AlatorreAlexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro
Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H. Adams, and E. Wesley Ely on
behalf of the COV-BARRIER Study Group*

Emory University School of Medicine, Rollins School of Public Health, Emory Vaccine

Center, and the Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA (Prof V C

Marconi, MD);

Translational Health Sciences, University of Bristol, Bristol, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK (Prof A V Ramanan FRCPCH, FRCP);

Eli Lilly and Company, Indianapolis, IN, USA (S de Bono MD PhD, C E Kartman RN BSN, V Krishnan MSc PhD, R Liao PhD, M L B Piruzeli MD, A Cardoso MD, S Chakladar PhD, B Crowe PhD, Paulo Reis MD, X. Zhang PhD, D. Adams PhD);

Swedish Center for Research and Innovation, Swedish Medical Center, Providence St.

Joseph Health, and Division of Allergy and Infectious Disease, Department of Medicine,

University of Washington, Seattle, WA, USA (J D Goldman, MD, MPH);

Instituto Nacional de Enfermedades Respiratorias, Mexico (Prof J Alatorre-Alexander, MD);

Pesquisare / Santo André, Brazil and Hospital Beneficência Portuguesa de São Caetano
do Sul / São Caetano do Sul, Brazil (R Pellegrini, MD);

Hospital Clinico San Carlos; Universidad Complutense, Madrid, Spain (Prof V Estrada, MD);

Oklahoma State University Medicine, Internal Medicine - Houston Center, Tulsa, OK, USA

(Prof M Som, DO);

Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Division of Allergy,

Pulmonary, and Critical Care Medicine, Department of Medicine at Vanderbilt University

Medical Center, and the Tennessee Valley Veteran's Affairs Geriatric Research Education

Clinical Center (GRECC), Nashville, TN, USA (Prof E W Ely, MD, MPH, MCCM)

*A complete list of members of the COV-BARRIER Study Group is provided in the

Supplementary Appendix.

Correspondence to:

Dr. Vincent C. Marconi

Emory University School of Medicine

Rollins School of Public Health

Health Sciences Research Building

1760 Haygood Dr NE, Room W325

Atlanta, GA 30322

Office 404-727-2343

Fax 404-712-4193

Email: vcmarco@emory.edu

ABSTRACT

Background: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, improved outcomes in a previous randomized controlled trial of hospitalized adults with COVID-19, in combination with remdesivir.

Methods: In this phase 3, global, double-blind, randomized, placebo-controlled trial, 1525 hospitalized adults with COVID-19 receiving standard of care (SOC) were randomly assigned (1:1) to once-daily baricitinib 4-mg (N=764) or placebo (N=761) for up to 14 days. SOC included systemic corticosteroids in ~79% of participants (dexamethasone ~90%). The primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28. A key secondary endpoint was all-cause mortality by day 28.

Results: Overall, 27.8% of participants receiving baricitinib vs 30.5% receiving placebo progressed (primary endpoint, odds ratio 0.85, 95% CI 0.67-1.08; p=0.18). The 28-day all-cause mortality was 8.1% for baricitinib and 13.1% for placebo, corresponding to a 38.2% reduction in mortality (hazard ratio [HR] 0.57, 95% CI 0.41-0.78; nominal p=0.002); 1 additional death was prevented per 20 baricitinib-treated participants. Reduction in mortality was seen for all prespecified subgroups of baseline severity (most pronounced for participants on high-flow oxygen/non-invasive ventilation at baseline [17.5%, baricitinib vs 29.4%, placebo; HR 0.52, 95% CI 0.33-0.80; nominal p=0.007]). The frequency of adverse events, serious adverse events, serious infections, and venous thromboembolic events was similar between groups.

Conclusions: While reduction of disease progression did not achieve statistical significance, treatment with baricitinib in addition to SOC (predominantly dexamethasone) significantly reduced mortality with a similar safety profile between groups of hospitalized COVID-19 participants.

(Funded by Eli Lilly and Company, under licence from Incyte Corporation; ClinicalTrials.gov number, NCT04421027.)

Hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) often experience an intense hyperinflammatory state that may lead to multiple organ dysfunction including acute respiratory distress syndrome (ARDS), septic shock, and death.¹⁻⁴ Despite recent treatment advances with remdesivir, dexamethasone, and tocilizumab, reducing mortality among hospitalized patients remains a critical unmet need.⁵⁻⁸

Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor⁹⁻¹¹ with a known anti-inflammatory profile in patients with autoimmune diseases. ¹²⁻¹⁴ In February 2020, baricitinib was identified by an artificial intelligence platform to have a potential coronavirus disease 19 (COVID-19) antiviral effect. ^{15,16} The biochemical inhibitory effects of baricitinib on human numb-associated kinases (AAK1, BIKE, and GAK) responsible for SARS-CoV-2 viral propagation were subsequently confirmed. ¹⁷ Baricitinib also reduced multiple cytokines and biomarkers implicated in COVID-19 pathophysiology. ¹⁸ Inspired by these findings, studies including small cohorts of COVID-19 hospitalized patients were conducted and provided first evidence of clinical improvement associated with baricitinib treatment. ^{19,20}

ACTT-2, a NIH-sponsored double-blind, randomized, placebo-controlled, phase 3 trial in hospitalized adults with COVID-19, found that baricitinib plus remdesivir was superior to remdesivir in reducing recovery time (p=0.03), with 28-day mortality reported (5.1% vs 7.8%, not statistically significant) and had fewer serious adverse events (SAEs).⁶ The Food and Drug Administration issued an Emergency Use Authorization in November 2020 for use of baricitinib, in combination with remdesivir, in hospitalized COVID-19 patients requiring oxygen supplementation.²¹

COV-BARRIER was designed to evaluate the efficacy and safety of baricitinib in combination with standard of care (SOC) for the treatment of hospitalized adults with COVID-19.

METHODS

This multi-center, randomized, double-blind, placebo-controlled, parallel-group, phase 3 trial included 101 centers from 12 countries in Asia, Europe, North and South America.

Participants were randomized 1:1 to placebo or baricitinib 4-mg. Participants were stratified according to the following baseline factors: disease severity, age, region, and use of corticosteroids for COVID-19. Baricitinib or placebo was administered orally (or crushed for nasogastric tube) and given daily, for up to 14 days or until discharge from hospital, whichever occurred first. Participants randomized to baricitinib 4-mg with baseline eGFR ≥30 to <60 mL/min/1.73 m² received baricitinib 2-mg. All participants received background SOC in keeping with local clinical practice for COVID-19 management, which could include corticosteroids, and/or antivirals. Dexamethasone use was permitted as described in the RECOVERY trial;⁷ higher corticosteroid doses were limited unless indicated for a concurrent condition. Prophylaxis for venous thromboembolic events (VTE) was required for all participants unless there was a major contraindication.

Efficacy and safety were evaluated up to day 28. Participants had additional post-treatment follow-up visits ~28 days after receiving their last dose of study drug and at ~day 60; data from the 60-day follow-up will be disclosed once available. Participant disposition is detailed in Figure 1 and includes reasons for discontinuation which include adverse events (AEs) (including death).

COV-BARRIER was conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All sites received approval from the authorized institutional review board. All participants (or legally authorized representatives) provided informed consent. An independent, external data monitoring committee (DMC) oversaw the study and evaluated unblinded interim data for efficacy, futility and safety analyses. An independent, blinded, clinical event committee adjudicated potential VTEs and deaths. The trial protocol and statistical analysis plan are available from the sponsor.

Participants

Eligible participants were ≥18 years of age, hospitalized with laboratory confirmed SARS-CoV-2 infection, had evidence of pneumonia or active, symptomatic COVID-19, and had ≥1 elevated inflammatory marker (C reactive protein, D-dimer, lactate dehydrogenase, ferritin). Participants were excluded if requiring invasive mechanical ventilation (National Institute of Allergy and Infectious Disease Ordinal Scale [NIAID-OS] 7) at study entry, receiving immunosuppressants (high dose corticosteroids, biologics, T cell or B cell-targeted therapies, interferon, or JAK inhibitors), or received convalescent plasma or intravenous immunoglobulin for COVID-19. Following disclosure of results from ACTT-2 showing participants without baseline oxygen support were not likely to progress, a protocol amendment was implemented to limit enrollment to participants requiring baseline oxygen support (OS 5/OS 6).

Outcomes

The composite primary endpoint was the proportion of participants who progressed to high-flow oxygen or non-invasive ventilation (OS 6), invasive mechanical ventilation or extracorporeal membrane oxygenation (OS 7), or death (OS 8) by day 28, in participants treated with baricitinib plus SOC compared to placebo plus SOC. The analysis of the primary endpoint does not differentiate outcomes subsequent to the progression. All deaths were assessed in a separate, key secondary endpoint of 28-day all-cause mortality. The primary objective was assessed in: Population 1 – all randomized participants, and; Population 2 – subpopulation of participants who, at baseline required oxygen supplementation and were not receiving systemic corticosteroids for COVID-19.

Key secondary outcomes were adjusted for multiplicity and included the following (evaluated at days 1-28, unless otherwise specified): all-cause mortality, proportion of participants with ≥1-point improvement on NIAID-OS or discharge from hospital at days 4, 7, 10,

Statistical Analyses

Power was calculated for the primary endpoint to succeed in ≥1 of the two primary populations, and the study was designed for the possibility of the sample size to be increased using an unblinded sample size re-estimation²² of the primary endpoint, as assessed during an interim analysis evaluated by external DMC (January 2021). The primary and secondary endpoints were analyzed according to the pre-specified analysis plan. In order to control the overall family-wise Type I error rate at a 2-sided alpha level of 0.05, a graphical testing procedure was used to test the primary and key secondary endpoints. Since the primary endpoint was not met (Table 2 and Figure S2), this manuscript reports nominal p-values for key secondary endpoints. Other analyses did not control for multiple comparisons.

Efficacy data were analyzed with the intent-to-treat population, defined as all randomized participants. Logistic regression was used for dichotomous endpoints, proportional odds model was used for ordinal endpoints, analysis of variance model was used for continuous endpoints, and mixed-effects model of repeated measure was used to assess continuous endpoints over time. Log-rank test and hazard ratio (HR) from Cox proportional hazard model were used for time-to-event analyses. These statistical models were adjusted for treatment and baseline stratification factors. Safety analyses included all randomized participants who received ≥1 dose of study drug and who did not discontinue the study for the reason of 'lost to follow-up' at the first post-baseline visit. Adverse events were inclusive of the 28-day treatment period. Statistical

RESULTS

Participants

Between June 11, 2020 and January 15, 2021, 1525 participants were randomly assigned to receive once-daily placebo plus SOC (N=761) or baricitinib 4-mg plus SOC (N=764); 83.1% of participants completed the 28-day treatment period (Figure 1). Of the 16.9% whom discontinued from the treatment period, 62.6% of discontinuations were due to death. No randomized participants were excluded from the intent-to-treat population; however, some participants were excluded from specific analyses due to the various information requirements of the different statistical methods as outlined in Table S2.

Baseline demographics and disease characteristics were balanced among treatment groups. The mean age of the participants was 57.6 years (SD 14.1), 63.1% were male, and enrollment was global (Table 1). Countries contributing >10% of enrollment included Brazil (21%), United States (21%), Mexico (18.4%), and Argentina (13.6%); participants were also enrolled in Europe, India, Japan, Korea and Russia. Overall, 61.6% of participants were white, 11.7% were Asian, and 5.0% were black or African American (with 10.3% of US participants of black or African American race). The majority (83.3%) of participants had symptoms ≥7 days prior to enrollment. Clinical status at baseline was OS 4 for 12.3%, OS 5 for 63.4% and OS 6 for 24.4% of participants. At baseline, the majority (79.3%) of participants received systemic corticosteroids, of which 91.3% received dexamethasone; 18.9% of participants received remdesivir (Table 1, Table S3). Of the participants that received remdesivir, 91.6% also received corticosteroids. The majority of participants (99.7%) had ≥1 pre-existing comorbid

condition. Select baseline demographics and clinical characteristics by baseline systemic corticosteroid use are described in Table S4.

Primary Endpoint

The composite primary endpoint of the proportion who progressed by day 28 was not statistically significant for participants treated with baricitinib versus placebo in Population 1 (27.8% vs 30.5%; odds ratio [OR] vs placebo 0.85, 95% confidence interval [CI] 0.67-1.08; p=0.18) or Population 2 (28.9% vs 27.1%; OR 1.12, 95% CI 0.58-2.16; p=0.73) (Table 2). The primary endpoint by the pre-specified baseline subgroups NIAID-OS and region are described in Tables S5 and S6, respectively. Approximately 3% fewer participants progressed compared to placebo; this trend was observed in the overall population and across all OS subgroups at baseline.

Key Secondary Endpoint – All-cause Mortality

Treatment with baricitinib reduced deaths, as measured by the key secondary endpoint of 28-day all cause-mortality. Mortality was 8.1% in the baricitinib group and 13.1% in the placebo group, corresponding to a 38.2% mortality reduction (HR 0.57, 95% CI 0.41-0.78; nominal p=0.002); overall, 1 additional death was prevented per 20 baricitinib-treated participants (Table 2, Figure 2A, Figure 3). A 64.6% reduction in mortality was observed for Population 2 (5.2% baricitinib, 14.7% placebo; HR 0.31, 95% CI 0.11-0.88; nominal p=0.030) (Figure 2B, Figure 3). A numerical reduction in mortality with baricitinib compared with placebo was observed for pre-specified baseline severity subgroups, including OS 4 (1.1% vs 4.1%; HR 0.24, 95% CI 0-2.18; nominal p=0.23) and OS 5 (5.9% vs 8.7%; HR 0.72, 95% CI 0.45-1.16; nominal p=0.11) (Figure 2C, Figure 3). A significant reduction in mortality was observed for baseline severity subgroup OS 6 with baricitinib compared with placebo (17.5% vs 29.4%; HR 0.52, 95% CI 0.33-0.80; nominal p=0.007) (Figure 2D, Figure 3); in this subgroup,1 additional

death was prevented per 9 baricitinib-treated participants. A significant reduction in mortality was observed with baricitinib compared with placebo for the pre-specified subgroups of participants treated at baseline with systemic corticosteroids (9.3% vs 13.9%; HR 0.63, 95% CI 0.45-0.89; nominal p=0.017), without systemic corticosteroids (3.3% vs 11.0%; HR 0.28, 95% CI 0.10-0.77; nominal p=0.011), or without remdesivir (8.0% vs 13.8%; HR 0.52, 95% CI 0.36-0.74; nominal p=0.001); for the 18.9% of participants with concomitant remdesivir treatment at baseline (91.6% also with corticosteroids) a numerical reduction in mortality was observed (Figure 2E-F, Figure S3, Figure 3). A numerical reduction in mortality was observed regardless of region for baricitinib compared with placebo (Figure 3, Table S7). Participant NIAID-OS status in the overall population at day 28 is shown in Figure 2G. Other secondary endpoints and the exploratory objective of pharmacokinetics are further described in the Supplementary Results, Table S8, and Figures S4, and S5.

Safety

The proportion of participants with ≥1 treatment-emergent AE (TEAE) was 44.5% in the baricitinib group and 44.4% in the placebo group; for SAEs, these proportions were 14.7% and 18%, respectively (Table 3). The most common SAEs are described in Table S9. The frequency of deaths reported as due to AE (1.6% vs 4.1%) and discontinuation of study treatment due to AE (7.5% vs 9.3%) were numerically lower with baricitinib versus placebo. Serious infections were reported for 8.5% of baricitinib-treated participants and 9.8% of placebo-treated participants (Table 3); among participants using corticosteroids at baseline, serious infections were similar between groups (9.6% vs 10.7%, respectively) (Table S10). There was a similar distribution of positively adjudicated VTEs (2.7% vs 2.5%) and major adverse cardiovascular events (1.1 % vs 1.2%,) with baricitinib and placebo groups, respectively. There were no reports of gastrointestinal perforations (Table 3). Safety data are described further in Tables 3, S10, and the Supplementary Results.

DISCUSSION

This international, multi-center study found no significant difference between baricitinib plus SOC and placebo plus SOC in the composite endpoint of disease progression. However, in a pre-specified key secondary endpoint, treatment with baricitinib reduced 28-day all-cause mortality by 38.2%, compared to placebo (HR 0.57, 95% CI 0.41-0.78; nominal p=0.002). In the overall population, the number needed to treat (NNT) with baricitinib to prevent 1 additional death was 20. Mortality reduction was also observed with baricitinib across baseline corticosteroid use and OS subgroups; in the OS 6 subgroup, the NNT with baricitinib to prevent 1 additional death was 9.

During the COV-BARRIER study, SOC changed significantly to include routine use of corticosteroids and guidelines^{23,24} were updated following the disclosure of results from the open-label RECOVERY trial in June, 2020, in which dexamethasone showed a 10.9% relative reduction in mortality compared to SOC (22.9% vs 25.7%; age-adjusted rate ratio 0.83, 95% CI 0.75-0.93; p<.001).⁷ The evaluation of tocilizumab (anti-IL-6) in RECOVERY showed a 12.1% relative risk reduction in 28-day mortality (29% vs 33% SOC; HR 0.86, 95% CI 0.77-0.96; p=.007).⁸ In ACTT-2, the 28-day mortality for baricitinib plus remdesivir was 5.1% and 7.8% for remdesivir alone; the study was not powered to detect a mortality difference between the groups.⁶ In COV-BARRIER, baricitinib plus SOC showed a 38.2% relative reduction in mortality compared to SOC including dexamethasone (8.1% vs 13.1%; HR 0.57, 95% CI 0.41-0.78; nominal p=0.002). To our knowledge, baricitinib shows the largest effect size on mortality for any COVID-19 treatment when compared to other randomized trials in hospitalized patients.⁵⁻⁸

The frequency of TEAEs, SAEs, infections, and VTEs were similar across the baricitinib and placebo groups and no new safety signals were detected in the acute care setting.

COV-BARRIER is the first multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the potential benefit and safety of baricitinib plus SOC, including

systemic corticosteroids and remdesivir, for the treatment of hospitalized adults with COVID-19. This study addresses an important knowledge gap related to the optimization of the treatment strategies for hospitalized patients with COVID-19. The enrollment timeline of COV-BARRIER is also relevant considering the complexity of evolving SOC, and heterogeneity of treatments across different geographies. All-cause mortality is the most relevant outcome in trials of patients hospitalized for COVID-19, and baricitinib plus SOC showed a meaningful reduction in mortality compared to placebo plus SOC, most notably for participants receiving high-flow oxygen or non-invasive ventilation.

Limitations of this study may have included the choice of disease progression, as measured by clinical status including oxygen support levels, as the primary outcome. Measuring progression based on the NIAID-OS reflects treatment decisions and may be influenced by the heterogeneity of clinical practice across different geographies. Baricitinib showed a consistent reduction in progression versus placebo in the three components of the composite primary endpoint, however, the difference did not reach statistical significance. In contrast, mortality is an objective and definitive patient outcome that does not change across geographies. Baricitinib may prevent mortality without reaching significance on the primary endpoint because mortality as an outcome integrates the multi-organ effects of COVID-19, which include but are not limited to pulmonary effects. Baricitinib's anti-inflammatory effects impact all organ systems, not only pulmonary function. ¹⁸ Longer-term efficacy and safety data will be evaluated in the ongoing COV-BARRIER study. ²⁵

The COV-BARRIER trial did not demonstrate a reduction in COVID-19 progression versus SOC using a composite endpoint. However, the secondary endpoint of 28-day all-cause mortality was significantly improved in participants randomized to baricitinib plus SOC as demonstrated by its efficacy in preventing 1 additional death for every 20 participants treated when compared to placebo plus SOC. The 38.2% reduction in all-cause mortality was observed in the entire study population and was consistent across pre-specified sub-groups of baseline

disease severity and geography, with a similar safety profile observed with baricitinib compared to SOC in hospitalized COVID-19 participants. These results suggest that baricitinib further reduces mortality beyond current SOC and can be a treatment option in the context of the global burden of mortality observed during this COVID-19 pandemic.

Data sharing statement

Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after the trial is completed, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.

Contributors

COV-BARRIER was designed jointly by consultant experts and representatives of the sponsor, Eli Lilly and Company. Data were collected by investigators and analyzed by the sponsor. All authors participated in data analysis and interpretation, draft and final manuscript review, and provided critical comment, including the decision to submit the manuscript for publication. The authors had full access to the data and verified the veracity, accuracy, and completeness of the data and analyses as well as the fidelity of this report to the protocol.

Declaration of Interests

VCM received research grants from CDC, Gilead Sciences, NIH, VA, and ViiV, received honoraria from Eli Lilly and Company, served as an advisory board member for Eli Lilly and Company and Novartis and participated as a study section chair for the NIH. AVR received research grants from Eli Lilly and Company, served as a speaker and/or consultant for AbbVie,

Eli Lilly and Company, Novartis, Pfizer, Roche, Sobi and UCB. SB, CEK, VK, RL AC, SC, BC, PR, XZ and DHA are employees and shareholders of Eli Lilly and Company. JDG received research support from Eli Lilly and Company, Regeneron Pharmaceuticals, and Gilead Sciences, grants from Eurofins Viracor, the Biomedical Advanced Research and Development Authority (administered by Merck), speaker fees from Gilead Sciences, Mylan Pharmaceuticals and advisory board fees from Gilead Sciences. RDP has no conflicts to disclose. JAA served as a speaker and scientific advisor for Astra Zeneca, Boehringer Ingelheim, BMS, Eli Lilly and Company, Foundation Medicine, Novartis, MSD, Roche and Takeda. VE received a research grant from Eli Lilly and Company. MS received research grants from Eli Lilly and Company, NIAID, Novartis and served as a board member for NBOME, Osteopathic Founders Foundation and COGMED. EWE received research grants from CDC, NIH and VA, and served as an unpaid consultant for Eli Lilly and Company.

Acknowledgements

The authors would like to thank the participants and study investigators and staff, including the COV-BARRIER Study Group (see Supplementary Appendix) who participated in the study, and the following colleagues from Eli Lilly and Company: Douglas Schlichting, PhD (formerly with Lilly) and Maher Issa, MS, Jennifer L. Milata, PhD, Theodore Spiro, MD, and Zhongkai Wang, PhD, for scientific input, Nicole Byers, PhD for medical writing support and manuscript preparation, and Roisin McCarthy, PhD for assisting with manuscript process support.

- 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
- 2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020.
- 3. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39:405-7.
- 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020.
- 5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 final report. N Engl J Med 2020;383:1813-26.
- 6. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021;384:795-807.
- 7. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704.
- 8. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial [Preprint]. MedRxiv, 2021. (Accessed April 20, 2021, at https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1.full.pdf.)
- Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298-307.
- 10. Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014;54:1354-61.
- 11. McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther 2019;21:183.
- 12. Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 2018;128:3041-52.
- 13. Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504-11.
- 14. Dörner T, Tanaka Y, Petri MA, et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial

- implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med 2020;7.
- 15. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395:e30-e1.
- 16. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and antiinflammatory treatments. Lancet Infect Dis 2020.
- 17. Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med 2020;12:e12697.
- 18. Sims JT, Krishnan V, Chang CY, et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol 2021;147:107-11.
- 19. Titanji BK, Farley MM, Mehta A, et al. Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. Clin Infect Dis 2021;72:1247-50.
- 20. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020;81:318-56.
- 21. FDA. Letter of Authorization: EUA for baricitinib (Olumiant), in combination with remdesivir (Veklury), for treatment of supsected or laboratory confirmed coronavirus disease 2019 (COVID-19). fda.gov, 2020. (Accessed April 20, 2021, at https://www.fda.gov/media/143822/download.)
- 22. Gao P, Ware JH, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat 2008;18:1184-96.
- 23. World Health Organization. COVID-19 clinical management: living guidance. 2021. (Accessed April 18, 2021, at https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.)
- 24. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2021. (Accessed April, 18, 2021, at https://www.covid19treatmentguidelines.nih.gov/.)
- 25. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2020 June 9. Identifier (NCT04421027), A study of baricitinib (LY3009104) in participants with COVID-19 (COV-BARRIER). 2020. (Accessed April, 18, 2021, at https://clinicaltrials.gov/ct2/show/NCT04421027.)

FIGURE LEGENDS

Figure 1. Trial profile.

SOC=standard of care. *Included in the intent-to-treat population. †Includes all randomized participants who received ≥1 dose of study drug and who did not discontinue the study for the reason of 'lost to follow-up' at the first post-baseline visit. ‡159 deaths total reported by day 28. There were an additional 3 deaths that occurred after treatment period disposition but within 28 days.

Figure 2. Kaplan-Meier estimates of mortality in the overall population, Population 2, by baseline NIAID-OS and by baseline systemic corticosteroid use, and distribution of NIAID-OS status over time.

For time-to-event endpoints, the p-value was calculated using an unstratified log-rank test. The HR with 95% CI was calculated using a Cox proportional hazards model. p-values are for comparisons of baricitinib 4-mg with placebo. For panels A-F, the number at risk at day 27 represent the number of participants with available data at day 28. Distribution of NIAID-OS status over time was analyzed in the intent-to-treat population with baseline OS and at least one post-baseline OS using last observation carried forward. Cl=confidence interval. HR=hazard ratio. NIAID-OS=National Institute of Allergy and Infectious Disease Ordinal Scale. OS=ordinal scale. OS score of 5=hospitalized, requiring supplemental oxygen. OS score of 6=hospitalized, receiving high-flow oxygen devices or non-invasive ventilation.

Figure 3. Mortality according to subgroup.

The HR with 95% CI was calculated using a Cox proportional hazards model. CI=confidence interval. HR=hazard ratio. NIAID-OS=National Institute of Allergy and Infectious Disease Ordinal Scale.

Table 1. Baseline demographics and clinical characteristics

	Placebo + SOC	Baricitinib 4-mg	All Participants
	(N=761)	+ SOC	(N=1525)
Characteristic		(N=764)	
Age, years	57.5 (13.8)	57.8 (14.3)	57.6 (14.1)
Distribution, n (%)			
<65	518 (68.1)	508 (66.5)	1026 (67.3)
≥65	243 (31.9)	256 (33.5)	499 (32.7)
Sex, n (%)			
Male	473 (62.2)	490 (64.1)	963 (63.1)
Female	288 (37.8)	274 (35.9)	562 (36.9)
Race, n (%)			
American Indian or Alaskan Native*	168/741 (22.7)	148/752 (19.7)	316/1493 (21.2)
Asian	94/741 (12.7)	80/752 (10.6)	174/1493 (11.7)
Black or African American	36/741 (4.9)	39/752 (5.2)	75/1493 (5.0)
Native Hawaiian or other Pacific	2/741 (0.3)	3/752 (0.4)	5/1493 (0.3)
Islander			
White	440/741 (59.4)	480/752 (63.8)	920/1493 (61.6)
Multiple	1/741 (0.1)	2/752 (0.3)	3 (0.2)

	Placebo + SOC Baricitinib 4-mg		All Participants
	(N=761)	+ SOC	(N=1525)
Characteristic		(N=764)	
Ethnicity, n (%)†			
Hispanic or Latino	46/158 (29.1)	54/162 (33.3)	100/320 (31.3)
Not Hispanic or Latino	94/158 (59.5)	92/162 (56.8)	186/320 (58.1)
Not reported	18/158 (11.4)	16/162 (9.9)	34/320 (10.6)
Geographic region, n (%)			
Europe‡	70 (9.2)	73 (9.6)	143 (9.4)
United States, including Puerto	158 (20.8)	162 (21.2)	320 (21.0)
Rico			
Rest of World§	533 (70.0)	529 (69.2)	1062 (69.6)
Country, n (%)			
Argentina	101 (13.3)	107 (14.0)	208 (13.6)
Brazil	165 (21.7)	172 (22.5)	337 (22.1)
Germany	11 (1.4)	9 (1.2)	20 (1.3)
India	31 (4.1)	19 (2.5)	50 (3.3)
Italy	10 (1.3)	15 (2.0)	25 (1.6)

	Dissala : COC	Dericitinih 4 ma	All Dartiainanta
	Placebo + SOC	Baricitinib 4-mg	All Participants
	(N=761)	+ SOC	(N=1525)
Characteristic		(N=764)	
Japan	19 (2.5)	19 (2.5)	38 (2.5)
Korea (Republic of)	20 (2.6)	16 (2.1)	36 (2.4)
Mexico	143 (18.8)	138 (18.1)	281 (18.4)
Russian Federation	54 (7.1)	58 (7.6)	112 (7.3)
Spain	42 (5.5)	45 (5.9)	87 (5.7)
United Kingdom	7 (0.9)	4 (0.5)	11 (0.7)
United States (including Puerto	158 (20.8)	162 (21.2)	320 (21.0)
Rico)			
BMI (kg/m²)	30.6 (6.6)	30.4 (6.4)	30.5 (6.5)
Disease duration of symptoms prior			
to enrollment, n (%)			
<7 days	116/756 (15.3)	137/762 (18.0)	253/1518 (16.7)
≥7 days	640/756 (84.7)	625/762 (82.0)	1265/1518 (83.3)
Score on NIAID-OS, n (%)			
4. Hospitalized, not requiring	97/756 (12.8)	89/762 (11.7)	186/1518 (12.3)
supplemental oxygen			

	Placebo + SOC	Baricitinib 4-mg	All Participants
	(N=761)	+ SOC	(N=1525)
Characteristic		(N=764)	
5. Hospitalized, requiring	472/756 (62.4)	490/762 (64.3)	962/1518 (63.4)
supplemental oxygen			
6. Hospitalized, receiving non-	187/756 (24.7)	183/762 (24.0)	370/1518 (24.4)
invasive ventilation or high-flow			
oxygen devices			
Concomitant medications of interest,			
n (%)			
Remdesivir	147/756 (19.4)	140/762 (18.4)	287/1518 (18.9)
Systemic corticosteroids	592/756 (78.3)	612/762 (80.3)	1204/1518 (79.3)
Dexamethasone	533/592 (90.0)	566/612 (92.5)	1099/1204 (91.3)
Pre-existing comorbid conditions of			
interest, n (%)			
Obesity	253 (33.2)	250 (32.7)	503 (33.0)
Diabetes (Type I and Type II)	233 (30.6)	224 (29.3)	457 (30.0)
Chronic respiratory disease	36 (4.7)	34 (4.5)	70 (4.6)
Hypertension	366 (48.1)	365 (47.8)	731 (47.9)

Table 2. Primary and key secondary outcomes in the intent-to-treat population

	Placebo + SOC		Baricitinib 4-mg + SOC	
	(N=761)		(N=764)	
			Comparison with	Nominal p
Outcome			placebo (95% CI)	value*
Primary outcome				
Progressed to high-flow oxygen, non-				
invasive ventilation oxygen, invasive				
mechanical ventilation†, or death by				
Day 28, (%)‡§				
Population 1¶**	30.5	27.8	0.85 (0.67 to 1.08)	0.18
Population 2††‡‡	27.1	28.9	1.12 (0.58 to 2.16)	0.73
Key secondary outcomes				
All-cause mortality, n (%)¶¶	100 (13.1)	62 (8.1)	0.57 (0.41 to 0.78)	0.002

	Placebo + SOC		Baricitinib 4-mg + SOC	
	(N=761)		(N=764)	
			Comparison with	Nominal p
Outcome			placebo (95% CI)	value*
Likelihood of overall improvement on the	;			
NIAID-OS**‡***				
Day 4			1.21 (1.00 to 1.47)	0.046
Day 7			1.25 (1.04 to 1.49)	0.017
Day 10			1.17 (0.97 to 1.41)	0.09
Day 14			1.28 (1.05 to 1.56)	0.017
≥1-point improvement on NIAID-OS or				
live discharge from hospital, (%)‡§**				
Day 4	21.1	25.2	1.26 (0.98 to 1.61)	0.07

	Placebo + SOC		Baricitinib 4-mg + SOC	
	(N=761)		(N=764)	
			Comparison with	Nominal p
Outcome			placebo (95% CI)	value*
Day 7	45.8	49.8	1.18 (0.95 to 1.46)	0.13
Day 10	63.5	65.0	1.07 (0.86 to 1.34)	0.54
Day 14	72.3	75.6	1.21 (0.95 to 1.55)	0.13
Median time to recovery (NIAID-OS)§§	11.0 (10.0 to 12.0)	10.0 (9.0 to 11.0)	1.11 (0.99 to 1.24)	0.15
Number of ventilator free days**†††	23.7 (0.39)	24.5 (0.39)	0.75 (-0.0 to 1.5)	0.06
Duration of hospitalization**†††	13.7 (0.40)	12.9 (0.40)	-0.76 (-1.6 to 0.0)	0.06
Change from baseline in oxygen				
saturation from <94% to ≥94%, n (%)‡				
Day 4	119/282 (42.2)	133/282 (47.2)	1.20 (0.86 to 1.69)	0.29

	Placebo + SOC		Baricitinib 4-mg + SOC	
	(N=761)		(N=764)	
			Comparison with	Nominal p
Outcome			placebo (95% CI)	value*
Day 7	146/282 (51.8)	146/282 (51.8)	0.97 (0.69 to 1.37)	0.88
Day 10	148/282 (52.5)	160/282 (56.7)	1.15 (0.81 to 1.63)	0.43
Day 14	166/282 (58.9)	166/282 (58.9)	0.95 (0.66 to 1.37)	0.79

Data are least squares mean (SE), median (95% CI), or n (%). Data were assessed from days 1-28, unless otherwise indicated. For dichotomous endpoints, a logistic regression model was used. For ordinal efficacy endpoints, a proportional odds model was used. For continuous endpoints, an analysis of variance (ANOVA) was used. All of these analyses had baseline randomization factors and treatment group in the model. For time-to-event endpoints, the p-value was calculated using an unstratified log-rank test. The hazard ratio with 95% CI was calculated using a Cox proportional hazards model. p values are for comparisons of baricitinib 4-mg with placebo. CI=confidence interval. N=number of participants in the analysis population. n=number of participants in the specified category. NIAID-OS=National Institute of Allergy and Infectious Disease Ordinal Scale. SE=standard error. SOC=standard of care. *To control the overall family-wise Type I error rate for multiple comparisons, the primary and key secondary endpoints were analyzed according to the prespecified statistical analysis plan with a graphical testing procedure. The primary endpoint was not met,

and therefore none of the key secondary endpoints were met within the graphical testing procedure. Nominal p values are shown. †Including extracorporeal membrane oxygenation. ‡Comparisons are odds ratio. §Percentages are calculated using multiple imputation method, which does not support a meaningful reporting of n. ¶All randomized participants. **Multiple imputation includes N=756 for placebo and N=762 for baricitinib. ††Participants who, at baseline, require oxygen supplementation and are not receiving dexamethasone or other systemic corticosteroids for the primary study condition. ‡‡Multiple imputation includes N=109 for placebo and N=96 for baricitinib. §§Comparisons are rate ratio. ¶¶Comparisons are hazard ratio. ***Results are represented for the overall odds ratio compared to placebo as this is derived from each individual contributing OS (OS1-8) at each time point. †††Comparisons are least squares mean difference.

Table 3. Safety overview in the safety population

	Placebo +	Baricitinib 4-
	SOC	mg + SOC
Event, n (%)	(N=752)	(N=750)
Treatment-emergent adverse event	334 (44.4)	334 (44.5)
Treatment-emergent adverse event by severity		
Mild	115 (15.3)	133 (17.7)
Moderate	89 (11.8)	90 (12.0)
Severe	130 (17.3)	111 (14.8)
Death due to adverse event*	31 (4.1)	12 (1.6)
Serious adverse event	135 (18.0)	110 (14.7)
Discontinuation from study treatment due to adverse event (including death)	70 (9.3)	56 (7.5)
Adverse event of special interest		
Treatment-emergent infection	123 (16.4)	119 (15.9)
Serious infections	74 (9.8)	64 (8.5)
Herpes simplex	4 (0.5)	1 (0.1)
Herpes zoster	4 (0.5)	1 (0.1)

	Placebo +	Baricitinib 4- mg + SOC
Event, n (%)	(N=752)	(N=750)
Tuberculosis	0	1 (0.1)
Opportunistic infections†	7 (0.9)	6 (0.8)
Venous thromboembolic event‡	19 (2.5)	20 (2.7)
Deep vein thrombosis	2 (0.3)	4 (0.5)
Pulmonary embolism	9 (1.2)	13 (1.7)
Other peripheral venous thrombosis	10 (1.3)	8 (1.1)
Major adverse cardiovascular event	9 (1.2)	8 (1.1)
Cardiovascular death	3 (0.4)	1 (0.1)
Myocardial infarction	4 (0.5)	4 (0.5)
Stroke	4 (0.5)	4 (0.5)
Gastrointestinal perforation	0	0

Data are n (%). Data were assessed from days 1-28. N=number of participants in the analysis population. n=number of participants in the specified category. SOC=standard of care. *Included in the overall mortality together with deaths due to disease progression. †Includes preferred terms Candida infection (n=1, baricitinib), Eye infection fungal (n=1, placebo), Fungal retinitis (n=1, baricitinib), Herpes zoster (n=3, placebo; n=1, baricitinib), Listeriosis (n=1, placebo), Oropharyngeal candidiasis (n=1, placebo), Pulmonary tuberculosis (n=1, baricitinib), Systemic

candida (n=2, baricitinib), and Varicella zoster virus infection (n=1, placebo). ‡Positively adjudicated by an independent external blinded clinical event committee.





Figure 1. Trial profile.



28 Baseline Day




Figure 3. Mortality according to subgroup.